These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 36978460)
21. Overcoming bacteriophage insensitivity in Staphylococcus aureus using clindamycin and azithromycinat subinhibitory concentrations. Liu S; Zhao Y; Hayes A; Hon K; Zhang G; Bennett C; Hu H; Finnie J; Morales S; Shearwin L; Psaltis AJ; Shearwin K; Wormald PJ; Vreugde S Allergy; 2021 Nov; 76(11):3446-3458. PubMed ID: 33930199 [TBL] [Abstract][Full Text] [Related]
22. Tobramycin-Treated Pseudomonas aeruginosa PA14 Enhances Streptococcus constellatus 7155 Biofilm Formation in a Cystic Fibrosis Model System. Price KE; Naimie AA; Griffin EF; Bay C; O'Toole GA J Bacteriol; 2016 Jan; 198(2):237-47. PubMed ID: 26483523 [TBL] [Abstract][Full Text] [Related]
23. Low-Dose Nitric Oxide as Targeted Anti-biofilm Adjunctive Therapy to Treat Chronic Pseudomonas aeruginosa Infection in Cystic Fibrosis. Howlin RP; Cathie K; Hall-Stoodley L; Cornelius V; Duignan C; Allan RN; Fernandez BO; Barraud N; Bruce KD; Jefferies J; Kelso M; Kjelleberg S; Rice SA; Rogers GB; Pink S; Smith C; Sukhtankar PS; Salib R; Legg J; Carroll M; Daniels T; Feelisch M; Stoodley P; Clarke SC; Connett G; Faust SN; Webb JS Mol Ther; 2017 Sep; 25(9):2104-2116. PubMed ID: 28750737 [TBL] [Abstract][Full Text] [Related]
24. Effect of pH on the antimicrobial susceptibility of planktonic and biofilm-grown clinical Pseudomonas aeruginosa isolates. Moriarty TF; Elborn JS; Tunney MM Br J Biomed Sci; 2007; 64(3):101-4. PubMed ID: 17910277 [TBL] [Abstract][Full Text] [Related]
25. In vitro evaluation of tobramycin and aztreonam versus Pseudomonas aeruginosa biofilms on cystic fibrosis-derived human airway epithelial cells. Yu Q; Griffin EF; Moreau-Marquis S; Schwartzman JD; Stanton BA; O'Toole GA J Antimicrob Chemother; 2012 Nov; 67(11):2673-81. PubMed ID: 22843834 [TBL] [Abstract][Full Text] [Related]
26. Pharmacodynamics of ceftazidime plus tobramycin combination dosage regimens against hypermutable Pseudomonas aeruginosa isolates at simulated epithelial lining fluid concentrations in a dynamic in vitro infection model. Tait JR; Bilal H; Kim TH; Oh A; Peleg AY; Boyce JD; Oliver A; Bergen PJ; Nation RL; Landersdorfer CB J Glob Antimicrob Resist; 2021 Sep; 26():55-63. PubMed ID: 34023531 [TBL] [Abstract][Full Text] [Related]
27. Tobramycin and bicarbonate synergise to kill planktonic Kaushik KS; Stolhandske J; Shindell O; Smyth HD; Gordon VD NPJ Biofilms Microbiomes; 2016; 2():16006. PubMed ID: 28721244 [TBL] [Abstract][Full Text] [Related]
28. Contribution of Drugs Interfering with Protein and Cell Wall Synthesis to the Persistence of Mangiaterra G; Carotti E; Vaiasicca S; Cedraro N; Citterio B; La Teana A; Biavasco F Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33562782 [TBL] [Abstract][Full Text] [Related]
29. Successful Intratracheal Treatment of Phage and Antibiotic Combination Therapy of a Multi-Drug Resistant Duplessis C; Warawa JM; Lawrenz MB; Henry M; Biswas B Antibiotics (Basel); 2021 Aug; 10(8):. PubMed ID: 34438996 [TBL] [Abstract][Full Text] [Related]
30. Efficacy of Lytic Phage Cocktails on Kifelew LG; Warner MS; Morales S; Thomas N; Gordon DL; Mitchell JG; Speck PG Viruses; 2020 May; 12(5):. PubMed ID: 32443619 [TBL] [Abstract][Full Text] [Related]
31. Filamentous Pseudomonas Phage Pf4 in the Context of Therapy-Inducibility, Infectivity, Lysogenic Conversion, and Potential Application. Gavric D; Knezevic P Viruses; 2022 Jun; 14(6):. PubMed ID: 35746731 [TBL] [Abstract][Full Text] [Related]
32. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis. Waters V; Ratjen F Cochrane Database Syst Rev; 2017 Oct; 10(10):CD009528. PubMed ID: 28981972 [TBL] [Abstract][Full Text] [Related]
33. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis. Waters V; Ratjen F Cochrane Database Syst Rev; 2015 Mar; (3):CD009528. PubMed ID: 25741986 [TBL] [Abstract][Full Text] [Related]
34. Routine susceptibility testing of four antibiotic combinations for improvement of laboratory guide to therapy of cystic fibrosis infections caused by Pseudomonas aeruginosa. Weiss K; Lapointe JR Antimicrob Agents Chemother; 1995 Nov; 39(11):2411-4. PubMed ID: 8585718 [TBL] [Abstract][Full Text] [Related]
35. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis. Smith S; Waters V; Jahnke N; Ratjen F Cochrane Database Syst Rev; 2020 Jun; 6(6):CD009528. PubMed ID: 32520436 [TBL] [Abstract][Full Text] [Related]
37. Isolation and characterization of a bacteriophage and its utilization against multi-drug resistant Pseudomonas aeruginosa-2995. Jamal M; Andleeb S; Jalil F; Imran M; Nawaz MA; Hussain T; Ali M; Das CR Life Sci; 2017 Dec; 190():21-28. PubMed ID: 28964812 [TBL] [Abstract][Full Text] [Related]
38. Treatment of chronic pseudomonas aeruginosa infection in cystic fibrosis patients with ceftazidime and tobramycin. Heilesen AM; Permin H; Koch C; Høiby N Scand J Infect Dis; 1983; 15(3):271-6. PubMed ID: 6417770 [TBL] [Abstract][Full Text] [Related]